Brief: Maia Biotechnology Accelerates Enrollment In Thio-101 Phase Ii Clinical Trial As Efficacy Is Observed In Dosed Patients

Maia Biotechnology

10/10/2023 18:33

Oct 10 (Reuters) - Maia Biotechnology Inc  MAIA.A :
    * MAIA BIOTECHNOLOGY ACCELERATES ENROLLMENT IN THIO-101
PHASE II
CLINICAL TRIAL AS EFFICACY IS OBSERVED IN DOSED PATIENTS
    * MAIA BIOTECHNOLOGY INC - THIO-101 ENROLLMENT PACE
CURRENTLY
EXCEEDS AVERAGE FOR SIMILAR NSCLC TRIALS
    * MAIA BIOTECHNOLOGY INC -  49 PATIENTS DOSED TO DATE; 37
HAVE
COMPLETED AT LEAST 1 POST BASELINE ASSESSMENT IN MAIA'S PHASE 2
CLINICAL TRIAL, THIO-101
    * MAIA BIOTECHNOLOGY INC - FOLLOWING U.S. FDA CLEARANCE OF
IND
APPLICATION, EXPECT TO MORE THAN DOUBLE NUMBER OF SITES IN NEAR
FUTURE

Source text for Eikon:  ID:nBw5b7dPNa 
Further company coverage:  MAIA.A 

 ((Reuters.Briefs@thomsonreuters.com;))